此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

2015年10月2日 更新者：Novartis Pharmaceuticals

A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension

This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients

研究概览

地位

完全的

条件

干预/治疗

详细说明

Summaries for treatment-emergent adverse events, serious adverse events and death were provided by the following actual treatment regimen (actual treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications.

Summaries for others than above were provided by the following treatment regimen (determined by the maximal treatment patients received) in addition to all patients: LCZ696 200mg, 400mg, 400mg+other hypertensive medications.

研究类型

介入性

注册 (实际的)

35

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 日本
    • Kanagawa
      • Yokohama-city、Kanagawa、日本、231-0023
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city、Kyoto、日本、606-8507
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-0031
        • Novartis Investigative Site
      • Hachioji-city、Tokyo、日本、192-0918
        • Novartis Investigative Site
      • Minato-ku、Tokyo、日本、105-7390
        • Novartis Investigative Site
      • Minato-ku、Tokyo、日本、108-0075
        • Novartis Investigative Site
      • Ota-ku、Tokyo、日本、143-0023
        • Novartis Investigative Site
      • Shibuya-ku、Tokyo、日本、150-0002
        • Novartis Investigative Site
      • Shinagawa-ku、Tokyo、日本、141-0032
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline

Exclusion Criteria:

  • Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg
  • History of angioedema, drug-related or otherwise, as reported by the patient
  • Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.
  • Patients have significant cardiovascular co-morbidities
  • Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.

Other protocol defined inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：非随机化
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：LCZ696 200 mg
All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
药品：LCZ696
LCZ696 200 mg tablet once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
实验性的：LCZ696 400 mg
All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
药品：LCZ696
LCZ696 200 mg tablet once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
实验性的：LCZ696 400 mg plus other hypertension (HTN) medications
All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
药品：LCZ696
LCZ696 200 mg tablet once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
药品：LCZ696
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths
大体时间：Week 8
Adverse events, serious adverse events deaths were monitored from screening to week 8.
Week 8

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in msSBP and msDBP at Week 8
大体时间：Baseline, 8 weeks
Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP measurements were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline value.
Baseline, 8 weeks
Percentage of Participants With Successful Blood Pressure (BP) Control in msSBP/msDBP at End of Study
大体时间：8 weeks
Successful BP control in patients with severe hypertension at the end of study treatment was defined as follows: msSBP/msDBP< 140/90 mmHg.
8 weeks
Percentage of Participants Achieving Successful msSBP Control at End of Study
大体时间：8 weeks
Successful msSBP control in patients with severe hypertension at the end of study treatment was defined as msSBP <140 mmHg.
8 weeks
Percentage of Participants Achieving Successful msDBP Control at End of Study
大体时间：8 weeks
Successful msDBP control in patients with severe hypertension at the end of study treatment was defined as msDBP < 90 mmHg.
8 weeks
Percentage of Participants With SBP Response at End of Study
大体时间：Baseline, 8 weeks
SBP response was defined as <140 mmHg or a reduction ≥ 20 mmHg from baseline.
Baseline, 8 weeks
Percentage of Participants With DBP Response at End of Study
大体时间：Baseline, 8 weeks
DBP response was defined as <90 mmHg or a reduction ≥ 10 mmHg from baseline.
Baseline, 8 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Novartis Pharmaceuticals

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年7月1日

初级完成 (实际的)

2013年2月1日

研究完成 (实际的)

2013年2月1日

研究注册日期

首次提交

2012年7月18日

首先提交符合 QC 标准的

2012年7月18日

首次发布 (估计)

2012年7月20日

研究记录更新

最后更新发布 (估计)

2015年10月23日

上次提交的符合 QC 标准的更新

2015年10月2日

最后验证

2015年10月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CLCZ696A1305

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅